Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) . Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available . A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
- Factor Xa inhibitors
- Nitric oxide
- School of Pharmacy and Biomolecular Sci - Clinical Principal Lecturer
- Medicines Optimisation Research and Enterprise Group
Mabley, J., Patel, J., Sayed, A., Arya, R., & Scutt, G. (2019). Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide. Thrombosis Research, 176, 36-38. https://doi.org/10.1016/j.thromres.2019.02.014